These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26625568)

  • 1. The "Negative" List.
    Allen LV
    Int J Pharm Compd; 2015; 19(4):311-3. PubMed ID: 26625568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 4. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 8. Application of standards for compounding.
    Newton DW
    J Am Vet Med Assoc; 1994 Jul; 205(2):232-4. PubMed ID: 7928584
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view.
    Fink JL
    Contemp Pharm Pract; 1979; 2(4):202-5. PubMed ID: 10244540
    [No Abstract]   [Full Text] [Related]  

  • 10. Judge allows bulk ingredients for compounding: ruling favors pharmacy, but FDA can still distinguish manufacturing, compounding.
    Cima G
    J Am Vet Med Assoc; 2011 Nov; 239(10):1266-68. PubMed ID: 22044321
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA culls nominations for compounding list.
    Landis NT
    Am J Health Syst Pharm; 1999 Jul; 56(14):1388, 1391. PubMed ID: 10428443
    [No Abstract]   [Full Text] [Related]  

  • 12. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 13. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additions and Modifications to the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Oct; 81(195):69668-77. PubMed ID: 27731962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final guidance for pharmacy compounding of human drug products under Section 503A.
    Blankenship CE
    Int J Pharm Compd; 2014; 18(5):379-80. PubMed ID: 25577886
    [No Abstract]   [Full Text] [Related]  

  • 16. President signs compounding law.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(1):7. PubMed ID: 24352171
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of compounding by the food and drug administration: a tale of 2 circuits.
    Williams KG
    J Pharm Pract; 2010 Oct; 23(5):502-6. PubMed ID: 21507854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nominations of Difficult to Compound Drugs TO THE U.S. FOOD AND DRUG ADMINISTRATION--PHARMACY COMPOUNDING ADVISORY COMMITTEE: PART 1.
    Allen LV
    Int J Pharm Compd; 2015; 19(5):389-90. PubMed ID: 26775446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixing it up: compounding pharmacy creates individualized medications.
    Wilson J
    Holist Nurs Pract; 2004; 18(2):108. PubMed ID: 15127780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.